Cypralis is privately held and started as a spinout from Selcia Ltd. in 2012. The founders are experts of combined 50 years of experience in the biology of cyclophilins and the chemistry of their inhibitors. Our headquarters is at St John's Innovation Centre, Cambridge, UK. The company has raised so far £4M from private investors, grants and collaborations. We operate a virtual model, using CROs and academic collaborations to conduct early discovery and pre-clinical activities. Pre-clinical and clinical development is done in China through our partnership with Farsight Medical Technology (Shanghai) CO., Ltd.
Please contact us to explore opportunities for collaboration or investment.